Table of Contents
Chapter I . Executive Overview of the Space
- Molecular Diagnostics in Cancer: Breakout of the Market By Types of Tests
and Their Value Proposition
- Prognostic vs. Predictive Markers for Cancer
- Personalized Medicine is Driving Cancer Treatment Decisions TODAY
- Commercialization Metrics: Drugs vs. Diagnostics
- The Lopsided Remuneration for Diagnostics: Personalized Medicine is
Changing This Paradigm
- Trajectory of Genomics-based Cancer Biomarker Tests, such as IVDMIAs, for
Personalized Medicine and Drivers for Market Acceptance
- Trajectory of Genomics-based Cancer Biomarker Tests, such as IVDMIAs, for
Personalized Medicine: Drivers and Challenges
- Quantitative Market Metrics: Market Sizes
- The Future of Cancer Personalized Medicine
Chapter II . Emerging Cancer Biomarkers for Personalized Medicine: microRNA-based, Epigenetics-based
- Potential Role of microRNAs and Epigenetics in Cancer Personalized
Medicine-The Potential Market Opportunities
- A microRNA Cancer Map
- microRNAs that are Associated with Human Cancers
- microRNAs that may Regulate Cancer-related Genes - I Particular microRNAs
may regulate specific cancer genes & their effect on cell function
- microRNAs that may Regulate Cancer-related Genes - II. Alteration of
microRNA expression in human malignancies
- Epigenetic Alterations in Cancer
- Predicted Impact of microRNA Diagnostics on Various Disease Areas and
Associated Timelines
- Predicted Impact of microRNA Therapeutics on Various Disease Areas and
Associated Timelines
- Rosetta Genomics Ltd., A Pioneer in Developing and Commercializing
microRNA-based Cancer Diagnostics
- Selected Market Participants Developing Epigenetics-based Cancer
Personalized Tests
Chapter III . RNAi Therapeutics Landscape for Cancer 32-37
Chapter IV. Market Analysis: Cancer Personalized Medicine
- Why Cancer Personalized Medicine? Value Delivered by the Diagnostic and
Associated Value by the Therapeutic
- Cancer Personalized Medicine: Anticancer drugs that can be used together
with a pharmacodiagnostic test
- Economics of Cancer Personalized Medicine
- Multigene Predictors of Clinical Outcome for Breast Cancer
- Comparison of Cost of Tests Across the Market Landscape for Breast Cancer
Testing
- Personalized Medicine in Other Cancers-A Complete Analysis of the Entire
Landscape
- Personalized Warfarin Therapy: Another Paradigm for the Personalized
Medicine Marketplace
- Cancer Personalized Medicine Worldwide Market Survey Data
Chapter V. Industry Participants in Personalized Medicine
- Abbott Molecular
- Affymetrix
- Agendia BV
- Celera
- Cepheid
- Clinical Data: PGXHealth, Cogenics, and Epidauros
- Dako Denmark A/S
- deCODE genetics
- DNA Direct
- DxS Ltd.
- Exact Sciences
- eXagen Diagnostics
- Gen-Probe
- Genelex
- Genentech
- Genomic Health
- Genzyme Genetics
- Illumina
- Luminex
- Monogram Biosciences
- Myriad Genetics
- Nanogen
- Osmetech Molecular Diagnostics
- Perlegen Sciences
- PGxI Laboratories
- Prometheus Laboratories
- Roche Diagnostics
- Siemens Medical Solutions Diagnostics
- Target Discovery
- Third Wave Technologies
- XDx
- Ventana Medical Systems/Roche
Appendix I . Research Methodology
Appendix II . Drug Metabolism Drives Drug Efficacy/ Toxicity
Appendix III . Regulatory Guidelines in Personalized Medicine
|
Related Report
|
View Cart
